Engineered Exosomes – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Engineered exosomes for delivering therapeutic molecules with high precision are a relatively new and less explored innovation area, classified as low impact in medium-term innovation due to lower patenting activity and lack of successful commercial products.
However, patent filing trends show promise with over 80% 3-year CAGR and patenting activity more than doubling in 2023. New companies entering this space have significantly increased, with a growing range of indications mentioned in patents, led by oncology, infectious diseases, and CNS disorders.
Big pharma has minimal activity in this space, with AstraZeneca being the only company among the Top 20 with patents filed. Most innovation is driven by startups, with companies like Evox, Anjarium, and Strm.Bio leading in patent filings.
The Engineered Exosome drugs landscape is dominated by Biologics, with a focus on Intravenous administration and Oncology therapies. Major players like Codiak BioSciences Inc and Evox Therapeutics Ltd are leading in drug development, particularly in Preclinical and Phase II trials.
Out of 84 clinical trials for Engineered Exosome drugs, Direct Biologics LLC & Vitti Labs conducted the highest number of trials, with Infectious Disease being the top indication, including 22 trials for COVID-19.
In the Engineered Exosome drug deals, there have been 77 deals totaling US$5.1 billion, with the United States and the United Kingdom standing out in deal volume and value since 2020. Fluctuations in deals in 2020 and a slight increase in 2023 may indicate market adjustments and strategic consolidations.

Scope

Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.

Key player: This represents a sample list of key players in each use case highlighted in the report.

Startups: This represents a sample list of emerging starups in each use case highlighted in the report.

University: This represents a sample list of leading universities in each use case highlighted in the report.

Key Highlights

1. Engineered Exosomes report is a high-impact innovation area in the Pharma industry, with a growing number of patents being filed and a focus on new indications such as Oncology and Infectious Diseases.

2. Big pharma companies like Codiak Biosciences dominate the patent activity in Engineered Exosomes with a dip in new companies filing patents in recent years.

3. Competitive intelligence shows that Entelexo Bio & Evox Ther in terms of portfolio size are among the leaders with strong innovation portfolios in Engineered Exosomes.

4. The drug landscape for Engineered Exosomes is dominated by innovator drugs, with a focus on Oncology and Central Nervous system, and major players like Codiak BioSciences Inc and Evox Therapeutics Ltd leading in drug development.

5. Clinical trials in Engineered Exosomes are dominated by Infectiousdisease trials, with the Direct Biologics LLC and Vitti Labs LLC leading in the number of trials.

Reasons to Buy

Stay Ahead with Our Engineered Exosomes Report:

Engineered exosome technology is revolutionizing the biotech and pharmaceutical industries. Our comprehensive report provides in-depth insights into the latest advancements, market analysis, and competitive intelligence to support strategic planning. It offers detailed data on patents, drugs, clinical trials, and partnership deals, ensuring you stay informed on critical developments. The report also tracks key regulatory and clinical updates, essential for navigating complex healthcare landscapes. By analyzing financial deals and funding trends, it highlights promising investment opportunities. This report is a vital tool for making informed, data-driven decisions and staying ahead in this rapidly evolving field.

Codiak BioSciences Inc
Evox Therapeutics Ltd
Rion Inc
ILIAS Biologics Inc
Shiftbio Co Ltd
Coya Therapeutics Inc
Medific Inc
ReNeuron Group Plc
Omnispirant Ltd
Curexsys GmbH
Exostemtech Co Ltd
Brexogen Inc
NextPhase Therapeutics
Tryptamine Therapeutics Ltd.

Table of Contents

Table of Contents

1. Innovation Insights

1.1 Innovation radar

1.2 Innovation s-curve

1.3 Innovation deep dive

1.4 Innovation deep dive – trending indications

1.5 Top companies Based on portfolio strength and temporal indicators

2. Competitive Insights

2.1 Key innovation leaders – big pharma

2.2.Key innovators – startups and small biotech

2.3 Key innovations – Universities and research institutions

2.4 Most cited patents

2.5 Insights from AI hub

3.Market Insights

3.1 Drugs

3.1.1 Key Players

3.1.2 Route of administration & drug type

3.1.3 Top therapy area & indication

3.2 Clinical Trials

3.2.1 Key Sponsors

3.2.2 Key development stages

3.3 Deals

3.3.1. Key Acquirers

3.3.2 Deal type distribution

3.3.3 Geographical distribution

Engineered Exosomes – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals standard reports
Currency USD
$2,499

Can be used by individual purchaser only

$7,497

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Engineered Exosomes – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Engineered Exosomes – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals in real time.

  • Access a live Engineered Exosomes – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.